To date, three reports have been published assessing rosiglitazone therapy inpatients with recurrent thyroid cancer as indicated by elevated Tg levels, butnegative pretreatment whole body iodine scans (Tg-positive, scan-negativethyroid cancer). Here, TG is linked to cancer.